L3VLUP
ProSign in

MLTX in the 13F filings

Moonlake Immunotherapeutics · CUSIP 61559X104

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023
Quarter end
30 Jun 2023
the date the book describes
Filed
14 Aug 2023
latest of these filings; the earliest 14 Aug 2023
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q1 2023 and Q2 2023; 0 listed it in both
Shares listed
227,439
combined, among listed positions
Reported value
$12m
combined, at the quarter end

Managers listing MLTX in Q2 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Schonfeld Strategic Advisors LLC117,960$6.0m0.05%Addedn.a.14 Aug 2023 (the filing on sec.gov)
Hudson Bay Capital Management LP60,000$3.1munder 0.1%Newnew14 Aug 2023 (the filing on sec.gov)
Woodline Partners LP49,479$2.5munder 0.1%Newnew14 Aug 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

There is no earlier quarter on file to compare with.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (2)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q2 2024 to 2 in Q2 2026

Tracked managers listing it, at least.

02468Q2 2023Q4 2023Q2 2024Q4 2024Q2 2025Q1 2026Q2 2026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
MLTX by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20233$12mn.a.n.a.
Q3 20235$155mn.a.n.a.
Q4 20237$257m61
Q1 20244$116m33
Q2 20243$130m30
Q3 20244$300m31
Q4 20244$350m30
Q1 20253$44m12
Q2 20251$15m10
Q3 20251$6.9m10
Q1 20262$75m1413
Q2 20262$65m1314

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

MLTX and LLY →MLTX and JNJ →MLTX and VRTX →Choose a stock to compare with MLTX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own MLTX, latest filings →Back to the 13F Explorer →